Pfizer Investigational Site
Tokyo, Japan
NCT Number: NCT01407016
The purpose of this study is to assess the safety, tolerability and pharmacokinetics of metronidazole following single and multiple intravenous infusion in healthy Japanese adult subjects.
Looking for future studies?
Notify Me20 year–55 year
All sexes
Interventional
Phase 1
Tokyo, Japan
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
On Day 1, subjects will receive a single dose of 500 mg metronidazole by intravenous infusion over 20 minutes. On Day 3 to Day 7, subjects will receive multiple doses of 500 mg metronidazole by intravenous infusion over 20 minutes 4 times a day (every 6 hours) for 5 days.
Time frame: Day 1 to Day 3
Time frame: Day 1 to Day 3
Time frame: Day 1 to Day 3
Time frame: Day 1 to Day 3
Time frame: prior to Day 3 and Day 6-8 morning dose and 6 hours post morning dose on Day 8
Time frame: Day 8 to Day 9
Time frame: Day 8 to Day 9
Time frame: Day 8 to Day 9
Time frame: Day 8 to Day 9
Time frame: Day 1 to Day 3
Time frame: Day 1 to Day 3
Time frame: Day 1 to Day 3
Time frame: Day 1 to Day 3
Time frame: prior to Day 3 and Day 6-8 morning dose and 6 hours post morning dose on Day 8
Time frame: Day 8 to Day 9
Time frame: Day 8 to Day 9
Time frame: Day 8 to Day 9
Pfizer
Industry
A Phase 1, Open Study To Assess The Safety, Tolerability And Pharmacokinetics Of Metronidazole Following Single And Multiple Intravenous Infusion In Healthy Japanese Adult Subjects
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01264055
Bronchial Diseases, Bronchiectasis
Stanford, California, United States
View Trial DetailsNCT07673484
Allergic Contact Dermatitis, Cicatrix
Küçükçekmece, Istanbul, Turkey (Türkiye)
View Trial DetailsNCT00342589
Bacterial Infections and Mycoses, Infection
Bethesda, Maryland, United States
View Trial DetailsNCT07256405
Bone, Fracture
Marseille, Bouches-du-Rhône, France
View Trial Details